Abilify how many mg

In clinical trials, Abilify was effective in treating schizophrenia in children ages 13 and older. In a study, Abilify treatment was compared with that of a placebo treatment with no active drug. Test scores from this test range from 30 to Higher scores indicate worse schizophrenia symptoms than lower scores indicate.

The study showed that:. Abilify is approved to treat manic or mixed episodes related to bipolar I disorder in children ages 10 years and older. For this condition, Abilify is approved for use on its own. In clinical trials, Abilify was effective in treating manic and mixed episodes of bipolar I disorder in children. One study looked at Abilify treatment compared with that of a placebo treatment with no active drug.

Test scores from this scale range from 0 to Higher scores indicate worse mania symptoms than lower scores indicate. For this use, Abilify can be prescribed for children ages 6 years and older. Autism symptoms vary across a spectrum. For example, some children with autism are able to function at a very high level, while other children with autism need more care. Autism is often diagnosed in children around the age of 2 years, when they may be having trouble with development.

Specifically, Abilify is used to treat irritability in children with autism. Irritability includes symptoms such as tantrums, injuring yourself, or having aggressive behaviors. Two different studies looked at Abilify treatment compared with that of a placebo treatment with no active drug. ABC test scores from this scale range from 0 to Higher ABC test scores indicate worse irritability symptoms than lower scores do. It causes involuntary movements and sounds that happen repetitively.

These movements and sounds are also called tics. Examples of movement-related tics include repetitive eye blinking or head jerking. Examples of sound-related tics include those that affect speech, such as repeating things that other people are saying. In some cases, tics can be dangerous. In fact, sometimes tics may cause a person to hurt themselves.

It often improves and may even disappear as people age into adulthood. The TTS scale ranges from 0 to Higher TTS scores indicate worse tic symptoms than lower scores indicate. For some of its approved uses, Abilify may be used in combination with other drugs. However, when treating major depressive disorder MDD , Abilify is always used with other drugs. MDD is also simply called depression. For MDD, Abilify is approved as an adjunct treatment.

Adjunct treatments are used in combination with other drugs to treat certain conditions. So as an adjunct treatment for MDD, Abilify is only used with other drugs. Below, we describe some of the drugs that may be used with Abilify. Or your doctor may change your medication regimen altogether. If you have questions about using medications with Abilify, talk with your doctor. They can recommend an appropriate treatment plan for your condition.

Your doctor may prescribe Abilify along with antidepressants to treat your condition. Some examples of antidepressants that may be taken with Abilify include:. Your doctor may prescribe Abilify along with mood stabilizers to treat your condition. Some examples of mood stabilizers that may be taken with Abilify include:. Your doctor may prescribe Abilify along with stimulants to treat your condition. Some examples of stimulants that may be taken with Abilify include:.

Your doctor may prescribe Abilify along with other antipsychotic drugs to treat your condition. Some examples of other antipsychotics that may be taken with Abilify include:. Other drugs are available that can treat your condition. Some may be a better fit for you than others. They can tell you about other medications that may work well for you. Note: Some of the drugs listed below are used off-label to treat these specific conditions.

This means that Abilify is only used with other drugs for MDD. Examples of other drugs that may be used to treat manic and mixed episodes related to bipolar I disorder include:. Examples of other drugs that may be used to treat schizophrenia include:. You may wonder how Abilify compares with other medications that are prescribed for similar uses. Here we look at how Abilify and Abilify Maintena are alike and different. Both Abilify and Abilify Maintena contain the same active drug: aripiprazole.

But even though these medications contain the same active drug, they act slightly differently inside your body. Abilify Maintena is approved to treat schizophrenia in adults.

The typical dosage of this drug is mg given once each month. Because Abilify and Abilify Maintena both contain the same active drug, their mild and serious side effects are the same. Also, because Abilify Maintena is an injectable medication, you may have pain at your injection site after receiving a dose of the drug. In some cases, you may actually start out by taking Abilify. Then if your condition responds well to the drug, you may start taking Abilify Maintena instead.

One study looked at people who took Abilify and then transitioned to Abilify Maintena. These people had more benefit in decreasing their schizophrenia symptoms when they switched to Abilify Maintena. But separate studies have found both Abilify and Abilify Maintena to be effective in treating schizophrenia. According to estimates on GoodRx. The cost also depends on whether you receive doses of either drug from a pharmacy or a medical facility.

Abilify and Abilify Maintena are both brand-name drugs. Brand-name medications usually cost more than generics cost. Like Abilify Maintena, discussed above, other medications are also prescribed for similar uses as Abilify is. Here we look at how Abilify and Rexulti are alike and different. Abilify contains the active drug aripiprazole , while Rexulti contains the active drug brexpiprazole.

Both Abilify and Rexulti are approved to treat schizophrenia. For this use, Abilify can be prescribed for adults and children ages 13 years and older. However, Rexulti is only approved for use in adults. Abilify and Rexulti are also both approved for use in adults as adjunct treatments for major depressive disorder MDD , which is also simply called depression.

Abilify and Rexulti both contain medications that treat schizophrenia and MDD. Therefore, these medications can cause very similar side effects, but some different ones as well. Below are examples of these side effects. These lists contain up to 10 of the most common mild side effects that can occur with Abilify, with Rexulti, or with both drugs when taken individually.

These lists contain examples of serious side effects that can occur with Abilify, with Rexulti, or with both drugs when taken individually. And these medications can also each be used in combination with other drugs to treat MDD.

The use of Abilify and Rexulti in treating schizophrenia has been directly compared in a clinical study. Abilify and Rexulti are both brand-name drugs. There is currently a generic form of Abilify, called aripiprazole. Brand-name medications usually cost more than generics. Like Rexulti, discussed above, other medications are prescribed for similar uses as Abilify is.

Here we look at how Abilify and Latuda are alike and different. Abilify contains the active drug aripiprazole , while Latuda contains the active drug lurasidone.

Both Abilify and Latuda are approved to treat schizophrenia in adults and children ages 13 years and older. Abilify and Latuda both contain drugs to treat schizophrenia. These lists contain up to 10 of the most common mild side effects that can occur with Abilify, with Latuda, or with both drugs when taken individually. These lists contain examples of serious side effects that can occur with Abilify, with Latuda, or with both drugs when taken individually. But separate studies have found both Abilify and Latuda to be effective in treating schizophrenia.

Abilify and Latuda are both brand-name drugs. Controlled substances are more likely than other medications to cause dependence. With dependence, your body needs the drug in order to feel normal. Abilify may cause dependence because it affects hormones inside your brain. And once your body adjusts to the changes caused by Abilify, you may become dependent on the drug. However, keep in mind that dependence of Abilify has not been studied in humans.

Because this medication may cause dependence and withdrawal symptoms, your doctor may recommend a different medication for you that has a lower risk of these complications. His symptoms included dizziness, nausea, anxiety, and muscle twitches. He also had insomnia trouble falling asleep or staying asleep. But keep in mind that this case only involved one person. If you have questions about withdrawal symptoms from Abilify, talk with your doctor or pharmacist.

With tapering, your doctor will slowly decrease your dose of the drug so that your body can adjust to the lower dose over time. Tapering off of Abilify can help decrease your risk of withdrawal symptoms. Keep in mind that the lowest dose that Abilify tablets are made in is 2 mg. Abilify affects the levels of two brain chemicals called dopamine and serotonin. Serotonin is important in controlling your mood and behavior.

Dopamine is important in regulating how you think and feel. And Abilify is approved to treat each of these conditions. Abilify may work to treat certain mental health conditions by balancing dopamine and serotonin levels. They can recommend whether you need medical attention. Yes, sometimes Abilify is used off-label to treat anxiety. And if you have questions about whether Abilify may be helpful in treating your anxiety, talk with your doctor. Yes, Abilify may cause you to have dangerous impulses or urges.

But all of these urges can be harmful, so you should tell your doctor, a family member, or a friend if you notice any impulses. In addition, your family and friends should also be keeping an eye out for any new impulses you may develop.

This is important for them to do because you might not notice certain urges developing. As soon as any urges or impulses are noticed, your doctor will likely decrease your dosage of Abilify. Or your doctor may have you stop taking the medication altogether. They can discuss with you the risks and benefits of treatment. These brain chemicals include dopamine and serotonin.

And serotonin is important in controlling your mood and behavior. Abilify may work by balancing your dopamine and serotonin levels. No, you should never take Abilify by snorting the drug. Abilify is meant to be taken by mouth. However, when you snort a drug through your nose, the drug goes directly into your bloodstream. In addition, snorting drugs can cause problems inside your nose, such as swelling or infections.

And in some cases , snorting drugs can even cause a hole to form between your nostrils. If you have questions about the best way to take your doses of Abilify, talk with your doctor or pharmacist. Acute treatment of manic or mixed episodes in bipolar I disorder as monotherapy; or as an adjunct to lithium or valproate. Adjunct to antidepressants for major depressive disorder MDD.

Irritability associated with autistic disorder. Orally disintegrating tabs: Dissolve on tongue; take without liquids.

Adjust dose to normal range when these drugs are withdrawn. Other dose adjustments: see full labeling. Irritability w. Increased mortality in elderly patients with dementia-related psychosis.

Suicidal thoughts and behaviors with antidepressant drugs. It should melt quickly. After the tablet has melted, you may swallow or take a sip of water. Follow your doctor's instructions on how to use the medicine. Aripiprazole may be taken with or without food. If your doctor tells you to take it a certain way, follow your doctor's instructions. The dose of this medicine will be different for different patients. Follow your doctor's orders or the directions on the label.

The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so. The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine. If you miss a dose of this medicine, take it as soon as possible.

However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing.

In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the suspect drug. Aripiprazole should be used with caution in patients with known cardiovascular disease history of myocardial infarction or ischemic heart disease, heart failure or conduction abnormalities , cerebrovascular disease, or conditions which would predispose patients to hypotension dehydration, hypovolemia, and treatment with antihypertensive medications.

Agranulocytosis has also been reported. Patients with clinically significant neutropenia should be carefully monitored for fever or other symptoms or signs of infection and treated promptly if such symptoms or signs occur. Conditions that lower the seizure threshold may be more prevalent in a population of 65 years or older. Somnolence including sedation led to discontinuation in 0. Despite the relatively modest increased incidence of these events compared to placebo, patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that therapy with ABILIFY does not affect them adversely.

Appropriate care is advised when prescribing aripiprazole for patients who will be experiencing conditions which may contribute to an elevation in core body temperature, eg, exercising strenuously, exposure to extreme heat, receiving concomitant medication with anticholinergic activity, or being subject to dehydration [see ADVERSE REACTIONS 6.

The possibility of a suicide attempt is inherent in psychotic illnesses, bipolar disorder, and major depressive disorder, and close supervision of high-risk patients should accompany drug therapy. ABILIFY has not been evaluated or used to any appreciable extent in patients with a recent history of myocardial infarction or unstable heart disease.

Aripiprazole has been evaluated for safety in 13, adult patients who participated in multiple-dose, clinical trials in schizophrenia, bipolar disorder, major depressive disorder, Dementia of the Alzheimer's type, Parkinson's disease, and alcoholism, and who had approximately patient-years of exposure to oral aripiprazole and patients with exposure to aripiprazole injection.

A total of patients were treated with oral aripiprazole for at least days and patients treated with oral aripiprazole had at least 1 year of exposure. Aripiprazole has been evaluated for safety in patients 6 to 17 years who participated in multiple-dose, clinical trials in schizophrenia, bipolar mania, or autistic disorder and who had approximately patient-years of exposure to oral aripiprazole.

A total of pediatric patients were treated with oral aripiprazole for at least days and pediatric patients treated with oral aripiprazole had at least 1 year of exposure. The conditions and duration of treatment with aripiprazole monotherapy and adjunctive therapy with antidepressants or mood stabilizers included in overlapping categories double-blind, comparative and noncomparative open-label studies, inpatient and outpatient studies, fixed- and flexible-dose studies, and short- and longer-term exposure.

Adverse events during exposure were obtained by collecting volunteered adverse events, as well as results of physical examinations, vital signs, weights, laboratory analyses, and ECG. Adverse experiences were recorded by clinical investigators using terminology of their own choosing.

In the tables and tabulations that follow, MedDRA dictionary terminology has been used to classify reported adverse events into a smaller number of standardized event categories, in order to provide a meaningful estimate of the proportion of individuals experiencing adverse events. The stated frequencies of adverse reactions represent the proportion of individuals who experienced at least once, a treatment-emergent adverse event of the type listed. An event was considered treatment emergent if it occurred for the first time or worsened while receiving therapy following baseline evaluation.

There was no attempt to use investigator causality assessments; ie, all events meeting the defined criteria, regardless of investigator causality are included.

Throughout this section, adverse reactions are reported. These are adverse events that were considered to be reasonably associated with the use of ABILIFY adverse drug reactions based on the comprehensive assessment of the available adverse event information. The figures in the tables and tabulations cannot be used to predict the incidence of side effects in the course of usual medical practice where patient characteristics and other factors differ from those that prevailed in the clinical trials.

Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatment, uses, and investigators. The cited figures, however, do provide the prescriber with some basis for estimating the relative contribution of drug and nondrug factors to the adverse reaction incidence in the population studied. The types of adverse reactions that led to discontinuation were similar for the aripiprazole-treated and placebo-treated patients.

The types of adverse reactions that led to discontinuation were similar between the aripiprazole-treated and placebo-treated patients. An examination of population subgroups did not reveal any clear evidence of differential adverse reaction incidence on the basis of age, gender, or race. Pediatric Patients 6 to 17 years with Autistic Disorder. The following findings are based on a pool of two placebo-controlled trials of patients with major depressive disorder in which aripiprazole was administered at doses of 2 mg to 20 mg as adjunctive treatment to continued antidepressant therapy.

The following findings are based on a pool of three placebo-controlled trials of patients with agitation associated with schizophrenia or bipolar mania in which aripiprazole injection was administered at doses of 5. Overall, in patients with agitation associated with schizophrenia or bipolar mania, there was little difference in the incidence of discontinuation due to adverse reactions between aripiprazole-treated 0.

This analysis, stratified by study, indicated that the only adverse reaction to have a possible dose response relationship, and then most prominent only with 30 mg, was somnolence [including sedation]; incidences were placebo, 7. In the study of pediatric patients 13 to 17 years of age with schizophrenia, three common adverse reactions appeared to have a possible dose response relationship: extrapyramidal disorder incidences were placebo, 5. In the study of pediatric patients 10 to 17 years of age with bipolar mania, four common adverse reactions had a possible dose response relationship at 4 weeks; extrapyramidal disorder incidences were placebo, 3.

In the adult schizophrenia trials, the objectively collected data did not show a difference between aripiprazole and placebo, with the exception of the Barnes Akathisia Scale aripiprazole, 0. In the pediatric 13 to 17 years schizophrenia trial, the objectively collected data did not show a difference between aripiprazole and placebo, with the exception of the Simpson Angus Rating Scale aripiprazole, 0. Similarly, in a long-term week , placebo-controlled trial of schizophrenia in adults, objectively collected data on the Simpson Angus Rating Scale for EPS , the Barnes Akathisia Scale for akathisia , and the Assessments of Involuntary Movement Scales for dyskinesias did not show a difference between aripiprazole and placebo.

In the adult bipolar mania trials with monotherapy aripiprazole, the Simpson Angus Rating Scale and the Barnes Akathisia Scale showed a significant difference between aripiprazole and placebo aripiprazole, 0. Changes in the Assessments of Involuntary Movement Scales were similar for the aripiprazole and placebo groups. In the bipolar mania trials with aripiprazole as adjunctive therapy with either lithium or valproate, the Simpson Angus Rating Scale and the Barnes Akathisia Scale showed a significant difference between adjunctive aripiprazole and adjunctive placebo aripiprazole, 0.

Changes in the Assessments of Involuntary Movement Scales were similar for adjunctive aripiprazole and adjunctive placebo. In the pediatric 10 to 17 years short-term bipolar mania trial, the Simpson Angus Rating Scale showed a significant difference between aripiprazole and placebo aripiprazole, 0. Changes in the Barnes Akathisia Scale and the Assessments of Involuntary Movement Scales were similar for the aripiprazole and placebo groups.

In the major depressive disorder trials, the Simpson Angus Rating Scale and the Barnes Akathisia Scale showed a significant difference between adjunctive aripiprazole and adjunctive placebo aripiprazole, 0.

Changes in the Assessments of Involuntary Movement Scales were similar for the adjunctive aripiprazole and adjunctive placebo groups. In the pediatric 6 to 17 years short-term autistic disorder trials, the Simpson Angus Rating Scale showed a significant difference between aripiprazole and placebo aripiprazole, 0.

Agitation Associated with Schizophrenia or Bipolar Mania. Objectively collected data on the Simpson Angus Rating Scale for EPS and the Barnes Akathisia Scale for akathisia for all treatment groups did not show a difference between aripiprazole and placebo.

Class Effect: Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment.

While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first generation antipsychotic drugs. An elevated risk of acute dystonia is observed in males and younger age groups. A between group comparison for 3-week to 6-week, placebo-controlled trials in adults or 4-week to 8-week, placebo-controlled trials in pediatric patients 6 to 17 years revealed no medically important differences between the aripiprazole and placebo groups in the proportions of patients experiencing potentially clinically significant changes in routine serum chemistry, hematology, or urinalysis parameters.

In the 6-week trials of aripiprazole as adjunctive therapy for major depressive disorder, there were no clinically important differences between the adjunctive aripiprazole-treated and adjunctive placebo-treated patients in the median change from baseline in prolactin, fasting glucose, HDL, LDL, or total cholesterol measurements. In a long-term week , placebo-controlled trial there were no medically important differences between the aripiprazole and placebo patients in the mean change from baseline in prolactin, fasting glucose, triglyceride, HDL, LDL, or total cholesterol measurements.

In 3-week trials in adults with mania with monotherapy aripiprazole, the mean weight gain for aripiprazole and placebo patients was 0. In the 6-week trial in mania with aripiprazole as adjunctive therapy with either lithium or valproate, the mean weight gain for aripiprazole and placebo patients was 0. In the trials adding aripiprazole to antidepressants, patients first received 8 weeks of antidepressant treatment followed by 6 weeks of adjunctive aripiprazole or placebo in addition to their ongoing antidepressant treatment.

The mean weight gain with adjunctive aripiprazole was 1. In the two short term, placebo-controlled trials in patients 6 to 17 years with autistic disorder, the mean increase in body weight in the aripiprazole group was 1. Between group comparisons for a pooled analysis of placebo-controlled trials in patients with schizophrenia, bipolar mania, or major depressive disorder revealed no significant differences between oral aripiprazole and placebo in the proportion of patients experiencing potentially important changes in ECG parameters.

Aripiprazole was associated with a median increase in heart rate of 2 beats per minute compared to no increase among placebo patients. In the pooled, placebo-controlled trials in patients with agitation associated with schizophrenia or bipolar mania, there were no significant differences between aripiprazole injection and placebo in the proportion of patients experiencing potentially important changes in ECG parameters, as measured by standard lead ECGs.

A similar profile was observed in a long-term study in bipolar disorder. All events assessed as possible adverse drug reactions have been included with the exception of more commonly occurring events. Although the reactions reported occurred during treatment with aripiprazole, they were not necessarily caused by it. Most adverse events observed in the pooled database of pediatric patients aged 6 to 17 years were also observed in the adult population. Additional adverse reactions observed in the pediatric population are listed below.

Most adverse reactions observed in the pooled database of adult patients treated with aripiprazole injection, were also observed in the adult population treated with oral aripiprazole.

Additional adverse reactions observed in the aripiprazole injection population are listed below. Due to its alpha adrenergic antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive agents. Aripiprazole also does not undergo direct glucuronidation. This suggests that an interaction of aripiprazole with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely. Agents that induce CYP3A4 eg, carbamazepine could cause an increase in aripiprazole clearance and lower blood levels.

Inhibitors of CYP3A4 eg, ketoconazole or CYP2D6 eg, quinidine, fluoxetine, or paroxetine can inhibit aripiprazole elimination and cause increased blood levels. When ketoconazole is given concomitantly with aripiprazole, the aripiprazole dose should be reduced to one-half of its normal dose. Other strong inhibitors of CYP3A4 itraconazole would be expected to have similar effects and need similar dose reductions; moderate inhibitors erythromycin, grapefruit juice have not been studied.

When the CYP3A4 inhibitor is withdrawn from the combination therapy, the aripiprazole dose should be increased. Aripiprazole dose should be reduced to one-half of its normal dose when quinidine is given concomitantly with aripiprazole. Other significant inhibitors of CYP2D6, such as fluoxetine or paroxetine, would be expected to have similar effects and should lead to similar dose reductions. When the CYP2D6 inhibitor is withdrawn from the combination therapy, the aripiprazole dose should be increased.

When carbamazepine is added to aripiprazole therapy, aripiprazole dose should be doubled. Additional dose increases should be based on clinical evaluation. When carbamazepine is withdrawn from the combination therapy, the aripiprazole dose should be reduced.

Aripiprazole is unlikely to cause clinically important pharmacokinetic interactions with drugs metabolized by cytochrome P enzymes. Additionally, aripiprazole and dehydro-aripiprazole did not show potential for altering CYP1A2-mediated metabolism in vitro.

There was no significant difference between aripiprazole coadministered with ethanol and placebo coadministered with ethanol on performance of gross motor skills or stimulus response in healthy subjects. No dosage adjustment of aripiprazole is required when administered concomitantly with famotidine.

No dosage adjustment of aripiprazole is required when administered concomitantly with valproate. No dosage adjustment of valproate is required when administered concomitantly with aripiprazole. A pharmacokinetic interaction of aripiprazole with lithium is unlikely because lithium is not bound to plasma proteins, is not metabolized, and is almost entirely excreted unchanged in urine.

No dosage adjustment of aripiprazole is required when administered concomitantly with lithium. No dosage adjustment of lithium is required when administered concomitantly with aripiprazole. No dosage adjustment of lamotrigine is required when aripiprazole is added to lamotrigine.

No dosage adjustment of dextromethorphan is required when administered concomitantly with aripiprazole. No dosage adjustment of warfarin is required when administered concomitantly with aripiprazole.

No dosage adjustment of omeprazole is required when administered concomitantly with aripiprazole. No dosage adjustment of aripiprazole is required when administered concomitantly with lorazepam. No dosage adjustment of escitalopram is required when aripiprazole is added to escitalopram. No dosage adjustment of venlafaxine is required when aripiprazole is added to venlafaxine. The steady-state plasma concentrations of sertraline and desmethylsertraline were not substantially changed when these antidepressant therapies were coadministered with aripiprazole.

Pregnancy Category C: In animal studies, aripiprazole demonstrated developmental toxicity, including possible teratogenic effects in rats and rabbits. There were no adverse effects on embryofetal or pup survival.

An increase in stillbirths and decreases in pup weight persisting into adulthood and survival were seen at this dose. These doses produced some maternal toxicity.